Table 4.
Demographic details and plasma nevirapine concentrations among children with different genotypes of CYP2B6 516G > T polymorphism
| Median (range) |
|||
|---|---|---|---|
| Variables | GG (n = 11) | GT (n = 12) | TT (n = 5) |
| Age (months) | 77.7 (16.4–140.8) | 80.1 (48.5–134.1) | 99.9 (63.3–127.3) |
| Weight (kg) | 17.4 (7.5–23.5) | 17.5 (14.0–27.0) | 16.0 (11.0–28.0) |
| WAZ score | −2.4 (−4.0 to −1.5) | −2.0 (−3.0–0.4) | −1.8 (−3.8 to −1.2) |
| Height (cm) | 104.0 (72.0–136.0) | 109.5 (95.0–131.0) | 113.0 (97.0–134.0) |
| HAZ score | −2.7 (−4.1 to −1.3) | −2.0 (−4.6–2.0) | −1.7 (−3.2–1.2) |
| WHZ score | −1.2 (−2.7–10.0) | −0.5 (−4.6–10.0) | −1.3 (−3.0–10.0) |
| Body mass index (kg/m2) | 13.9 (12.0–16.1) | 14.5 (9.1–17.1) | 13.7 (11.7–15.6) |
| Body surface area (m2) | 0.7 (0.4–0.9) | 0.7 (0.6–1.0) | 0.7 (0.6–1.0) |
| Duration of ART (months) | 14 (1–54) | 14 (1–54) | 13.5 (1–33) |
| CD4, % | 12.5 (5–23) | 18 (5–27) | 7 (3–11) |
| Daily prescribed NVP dose (mg/m2/day), d4T:3TC:NVP | |||
| 6:30:50 | 279 (195–320) | 270a | 293a |
| 10:40:70 | 314 (302–327) | 280 (83–400) | 342 (239–446) |
| 30:150:200 | 238 (222–430) | 299 (233–388) | 375 (361–388) |
| Daily prescribed NVP dose (mg/kg/day), d4T:3TC:NVP | |||
| 6:30:50 | 15.6 (13.3–16.0) | 11.4a | 13.0a |
| 10:40:70 | 14.3 (14.1–14.5) | 12.5 (3.3–18.7) | 18.0 (13.6–22.3) |
| 30:150:200 | 10.8 (8.7–17.0) | 12.4 (9.1–16.6) | 14.6 (14.3–15.0) |
| Trough concentration (µg/mL) | 3.1 (1.7–7.7) | 4.0 (2.3–10.0) | 9.5 (6.7–10.2)b |
| 2 h concentration (µg/mL) | 5.7 (2.5–13.2) | 5.6 (2.5–13.0) | 12.6 (8.1–16.3)b |
d4T, stavudine; NVP, nevirapine; 3TC, lamivudine.
aValue represents a single observation.
bP < 0.01 (Kruskal–Wallis test).